Ceapro Inc V.CZO

Shareholder-Value

[fossi_2002]

In soccer you would say it's 0:2 against Ceapro.
(Beta Glucan + Energy Drink)

The transformation of Ceapro into a biotechnology company is making slow progress. A lot of fantasy but little tangible. Everything is taking longer than mostly predicted.

Unfortunately, most of the opinions here on the bullboard are either all white or all black. More realistic is often neither one nor the other, but a wide variety of shades of gray.

The 3rd quarter results disappointed shareholders so much that looking back at the 1st half of the year didn't help either.
On the contrary, the permanent share sales suggest that the 4th quarter figures may also disappoint.

Since Gilles has always been at war with the concept of "shareholder value" in the past, shareholders can only expect a turnaround when there is fundamental positive news.

On December 2, CIAO attached an interview of Gilles and, when asked about a dividend, only laughed and made it clear that the company under his management is exclusively going in the direction of reinvestment. (play at 1.16.15 min)

If we shareholders would only receive what Gilles pays out as salary (approx. 1c per share), I would be satisfied in the current situation. But even if you demand only 10-15% of the net profit, that is an imposition for him.

Shareholders should provide the capital and otherwise keep their mouths shut. That's what shareholder value looks like to him.

[prophetoffactz]

"In soccer you would say it's 0:2 against Ceapro. (Beta Glucan + Energy Drink)" Realistically development stage assets take a long and winding road through trial-and-error. It can take 10 years to develop them ore more. That they make it to success in a straight line is largely a fantasy. Most early-stage R&D fails. CZO's oat beta glucan was set aside for now because CZO has

[Ciao]

The issue most investors have is the time scale of those arrows. While most of us understand the need to pivot and redesign, the time scale needs to be compressed. If academia is being used say for R&D for the functional drink perhaps private labs can be employed. Sure the cost is higher, however the company is well funded, and if additional capital is needed, perhaps some PR to generate

[Hopeforthebest]

Unfortunately in your attempt to sugar coat the ineptness of management you show just how wrong you are. Shareholders or the majority are not stupid, unlike the stupid pumpers of this stock. Shareholders know it takes time to develop a product/process and this does not happen over night. But when you take that timeline and add to it a total disregard by management to not communicate then you have

[prophetoffactz]

"If academia is being used say for R&D for the functional drink perhaps private labs can be employed. Sure the cost is higher..." Dr. Todd Hoare is one of the top 1% in his field. Dr. Kjetil Ask has worked with a who's who of the IPF industry and has published with Boehringer Ingleheim on nintedanib, etc. Dr. Martin Kolb is Jack Gauldie Boehringer Ingleheim Chair at McMaster

[Ciao]

The suggestion was for the bioavailability study at UofA where work was related to the functional drink. A private lab does not mean a Ceapro internal lab but a 3rd party lab. https://cbdchoice.com/everything-you-need-to-know-about-third-party-lab-testing/ I'm good with the YBG related work carriied out at McMaster and clinical studies at MHI esp the former given the SME there.  

[Stinzo]

lets do some basic math cash and equivalents by end of 2022 can be estimated at 17 M. at 0.60 the company is worth 47 M.  47-17 = 30 M for a company that nets 3 M a year ... or 10% net margin  not bad if there is any slight chance that it goes back up. however, see you next time in April/May happy 2022/2023